NEW YORK, Nov. 24, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ('Seelos' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-30 a reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m.

纽约，2023年11月24日/PRNewswire/--Seelos Therapeutics，Inc。（纳斯达克股票代码：SEEL）（'Seelos'或'公司'），一家专注于开发中枢神经系统治疗方法的临床阶段生物制药公司今天，疾病和罕见疾病宣布其董事会批准其流通股的1:30反向股票分拆，截至上午12:01生效。

Eastern Time on Tuesday, November 28, 2023..

东部时间2023年11月28日星期二。。

The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Tuesday, November 28, 2023. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol 'SEEL' with the new CUSIP number, 81577F208.

本公司普通股将于2023年11月28日星期二上市时开始反向股票分拆调整交易。反向股票分拆后，本公司普通股将继续在纳斯达克资本市场以符号“SEEL”与新的CUSIP号码81577F208进行交易。

The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market..

反向股票分拆旨在使公司重新遵守普通股股份1.00美元的最低投标价格要求，以便在纳斯达克资本市场继续上市。。

At the effective time of the reverse split, every 30 issued and outstanding shares of the Company's common stock will be converted automatically into one share of the Company's common stock without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.

在反向分裂生效时，本公司普通股每30股已发行和已发行股份将自动转换为本公司普通股的一股，而每股par值无任何变化。反向股票拆分不会发行分数股，反向股票拆分产生的分数股将四舍五入到最近的整体股。

The reverse stock split will reduce the number of authorized shares of the Company's common stock from 480,000,000 shares to 16,000,000 shares and the ownership percentage of each stockholder will remain unchanged other than as a result of fractional shares. In addition, the reverse stock split will apply to the Company's common stock issuable upon the exercise of the Company's outstanding warrants and stock options, with proportionate adjustments to be made to the exercise prices thereof and under the Company's equity incentive plans, as applicable..

反向股票分割将使本公司普通股的授权股份数量从48000000股减少至16000000股，除分数股外，每个股东的所有权百分比将保持不变。此外，反向股票分割将适用于行使本公司未行使认股权证及股票期权时可发行的本公司普通股，并根据本公司的行使价格及本公司的股权激励计划（如适用）作出相应调整。。

The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 167.7 million to approximately 5.6 million.

反向股票拆分将使本公司普通股已发行和已发行股份数量从约1.677亿减少至约560万。

About Seelos Therapeutics:

关于Seelos Therapeutics：

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), as well as early-stage programs in Huntington's disease, Alzheimer's disease, and Parkinson's disease..

Seelos Therapeutics，Inc.是一家临床阶段的生物制药公司，致力于开发和开发新型疗法，以满足未满足的医疗需求，从而为中枢神经系统（CNS）疾病和其他罕见疾病患者带来益处。该公司强大的投资组合包括针对严重抑郁症（MDD），肌萎缩侧索硬化症（ALS）和脊髓小脑性共济失调（SCA）等急性自杀意念和行为（ASIB）以及亨廷顿舞蹈病，阿尔茨海默病和帕金森病。。

Forward-Looking Statements:

前瞻性声明：

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the reverse stock split and the timing thereof, the potential impact of the reverse split on the bid price of the Company's common stock, the potential for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market and the expected number of shares of common stock to be outstanding following the reverse stock split.

本新闻稿中所作的声明本质上不是历史性的，构成了1995年“私人证券诉讼改革法”提供的安全港的前瞻性声明。这些陈述除其他外，还包括有关反向股票拆分及其时间安排的陈述，反向拆分对本公司普通股投标价格的潜在影响，公司有可能重新遵守股票在纳斯达克资本市场继续上市的普通股1.00美元的最低投标价格要求，以及反向股票分裂后预期发行的普通股股份数量。

These statements are based on our current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties involved include those associated with general economic and market conditions, as well as other risk factors and matters set forth in our periodic filings with the SEC, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

这些陈述基于我们目前的预期和信念，并受到许多因素和不确定性的影响，这些因素和不确定性可能导致实际结果与前瞻性陈述中描述的结果大不相同。所涉及的风险和不确定性包括与一般经济和市场状况相关的风险和不确定性，以及我们与SEC定期提交的其他风险因素和事项，包括我们最近关于表格10-K的年度报告以及随后关于表格的季度报告10-Q。

Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise.

尽管我们认为前瞻性陈述中反映的期望是合理的，但我们不知道我们的期望是否正确。警告您不要过分依赖这些前瞻性声明，这些声明仅在本协议签署之日起生效，即使我们随后在我们的网站或其他网站上提供。

We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws..

我们不承担任何更新，修改或澄清这些前瞻性陈述的义务，无论是由于新信息，未来事件还是其他原因，除非适用证券法可能要求。。

Contact Information

联系信息

Anthony MarcianoChief Communications OfficerSeelos Therapeutics, Inc. (Nasdaq: SEEL)300 Park Avenue, 2nd FloorNew York, NY 10022(646) 293-2136[email protected]

Anthony MarcianoChief Communications OfficerSeelos Therapeutics，Inc。（纳斯达克：SEEL）300 Park Avenue，2nd FloorNew York，NY 10022（646）293-2136[电子邮件保护]

Mike MoyerManaging DirectorLifeSci Advisors, LLC250 West 55th St., Suite 3401New York, NY 10019(617) 308-4306[email protected]

Mike Moyermangering DirectorLifeSci Advisors，LLC250 West 55th St.，Suite 3401New York，NY 10019（617）308-4306[电子邮件保护]

SOURCE Seelos Therapeutics, Inc.

资料来源Seelos Therapeutics，Inc。